Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Income from Continuing Operations rose 818.75% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10616.1%. This contributed to the annual value of -$14.0 million for FY2024, which is 8739.19% up from last year.
  • As of Q3 2025, Heron Therapeutics' Income from Continuing Operations stood at -$4.1 million, which was up 818.75% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Income from Continuing Operations ranged from a high of $4.2 million in Q4 2024 and a low of -$62.9 million during Q1 2022
  • Its 5-year average for Income from Continuing Operations is -$27.2 million, with a median of -$24.9 million in 2023.
  • As far as peak fluctuations go, Heron Therapeutics' Income from Continuing Operations tumbled by 2074.11% in 2022, and later surged by 16573.57% in 2025.
  • Heron Therapeutics' Income from Continuing Operations (Quarter) stood at -$53.5 million in 2021, then surged by 61.98% to -$20.4 million in 2022, then surged by 49.79% to -$10.2 million in 2023, then skyrocketed by 140.83% to $4.2 million in 2024, then plummeted by 198.08% to -$4.1 million in 2025.
  • Its Income from Continuing Operations stands at -$4.1 million for Q3 2025, versus -$1.6 million for Q2 2025 and $3.2 million for Q1 2025.